What is the first-line therapy for metastatic renal cell carcinoma (RCC)?

Updated: Feb 19, 2021
  • Author: Kush Sachdeva, MD; Chief Editor: E Jason Abel, MD  more...
  • Print

In recent years, clinical trials have established targeted therapy as the most common first-line treatment in patients with metastatic disease. Although the optimal treatment strategy continues to evolve, three agents that target angiogenesis (sunitinib, bevacizumab, and pazopanib) and a mammalian target of rapamycin (mTOR)–targeted therapy (temsirolimus) have been approved as front-line agents. High-dose interleukin-2 (IL-2) and axitinib can be used in selected patients.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!